Leukocyte Reduction of Red Blood Cell Transfusions Does not Decrease Allosensitization Rates in Potential Kidney Transplant Candidates

Journal of the American Society of Nephrology

Volumn 15, Issue 3, 2004, Pages 818-824

  Karpinski, Martin ^a   Pochinco, Denise ^b   Dembinski, Iga ^b   Laidlaw, Willie ^b   Zacharias, James ^a   Nickerson, Peter ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Immunogenetics Laboratory   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLOIMMUNITY; ALLOSENSITIZATION; ARTICLE; BLOOD TRANSFUSION; CANCER PATIENT; CONTROLLED STUDY; DISEASE ASSOCIATION; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOLOGIC MALIGNANCY; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHYSICIAN; PREGNANCY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIZATION;

EID: 1542318907     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000115399.80913.B1     Document Type: Article

References (53)

1. Vella JP, O'Neill D, Atkins N, Donohoe JF, Walshe JJ: Sensitization to human leukocyte antigen before and after the introduction of erythropoietin. Nephrol Dial Transplant 13: 2027-2032, 1998
2. Hardy S, Lee SH, Terasaki PI: Sensitization 2001. Clin Transpl 271-278, 2001
3. Hiesse C, Busson M, Buisson C, Farahmand H, Bierling P, Benbunan M, Bedrossian J, Aubert P, Glotz D, Loirat C, Rondeau E, Viron B, Bleux H, Lang P: Multicenter trial of one HLA-DR-matched or mismatched blood transfusion prior to cadaveric renal transplantation. Kidney Int 60: 341-349, 2001
4. Opelz G, Vanrenterghem Y, Kirste G, Gray DW, Horsburgh T, Lachance JG, Largiader F, Lange H, Vujaklija-Stipanovic K, Alvarez-Grande J, Schott W, Hoyer J, Schnuelle P, Descoeudres C, Ruder H, Wujciak T, Schwarz V: Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation 63: 964-967, 1997
5. Alexander JW, Light JA, Donaldson LA, Delmonico FL, Diethelm AG, Wilkinson A, Rosenthal JT, Thistlethwaite JR, Hunsicker LG, Matas AJ, First MR, Reinsmoen NL, Rose SM: Evaluation of pre- and posttransplant donor-specific transfusion/cyclosporine A in non-HLA identical living donor kidney transplant recipients. Cooperative Clinical Trials in Transplantation Research Group. Transplantation 68: 1117-1124, 1999
6. Cecka JM: The UNOS renal transplant registry. Clin Transpl 1-18, 2001
7. Meier-Kriesche HU, Port FK, Ojo AO, Rudich SM, Hanson JA, Cibrik DM, Leichtman AB, Kaplan B: Effect of waiting time on renal transplant outcome. Kidney Int 58: 1311-1317, 2000
8. Meier-Kriesche HU, Kaplan B: Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: A paired donor kidney analysis. Transplantation 74: 1377-1381, 2000
9. Dzik S, Aubuchon J, Jeffries L, Kleinman S, Manno C, Murphy MF, Popovsky MA, Sayers M, Silberstein LE, Slichter SJ, Vamvakas EC: Leukocyte reduction of blood components: Public policy and new technology. Transfus Med Rev 14: 34-52, 2000
10. Sanfilippo FP, Bollinger RR, MacQueen JM, Brooks BJ, Koepke JA: A randomized study comparing leukocyte-depleted versus packed red cell transfusions in prospective cadaver renal allograft recipients. Transfusion 25: 116-119, 1985
11. Christiaans MH, van Hooff JP, Nieman F, van den Berg-Loonen EM: HLA-DR matched transfusions: Development of donor-specific T- and B-cell antibodies and renal allograft outcome. Transplantation 67: 1029-1035, 1999
12. Gebel HM, Bray RA: Sensitization and sensitivity: Defining the unsensitized patient. Transplantation 69: 1370-1374, 2000
13. Karpinski M, Rush D, Jeffery J, Exner M, Regele H, Dancea S, Pochinco D, Birk P, Nickerson P: Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 12: 2807-2814, 2001
14. DeNofrio D, Rho R, Morales FJ, Kamoun M, Kearns J, Dorozinsky C, Rosengard BR, Acker MA, Loh E: Detection of anti-HLA antibody by flow cytometry in patients with a left ventricular assist device is associated with early rejection following heart transplantation. Transplantation 69: 814-818, 2000
15. Health Canada Directive D98-01: Implementation of Prestorage Leukoreduction of Cellular Blood Components, Nov. 2, 1998. Available at: www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/bgtd/leukodep_e.pdf
16. Opelz G, Graver B, Mickey MR, Terasaki PI: Lymphocytotoxic antibody responses to transfusions in potential kidney transplant recipients. Transplantation 32: 177-183, 1981
17. Jordan SC, Vo A, Bunnapradist S, Toyoda M, Peng A, Puliyanda D, Kamil E, Tyan D: Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 76: 631-636, 2003
18. Jordan S, Cunningham-Rundles C, McEwan R: Utility of intravenous immune globulin in kidney transplantation: Efficacy, safety, and cost implications. Am J Transplant 3: 653-664, 2003
19. Sonnenday CJ, Ratner LE, Zachary AA, Burdick JF, Samaniego MD, Kraus E, Warren DS, Montgomery RA: Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant Proc 34: 1614-1616, 2002
20. Schiffer CA, Dutcher JP, Aisner J, Hogge D, Wiernik PH, Reilly JP: A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 62: 815-820, 1983
21. Murphy MF, Metcalfe P, Thomas H, Eve J, Ord J, Lister TA, Waters AH: Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol 62: 529-534, 1986
22. Sniecinski I, O'Donnell MR, Nowicki B, Hill LR: Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 71: 1402-1407, 1988
23. Andreu G, Dewailly J, Leberre C, Quarre MC, Bidet ML, Tardivel R, Devers L, Lam Y, Soreau E, Boccaccio C: Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 72: 964-969, 1988
24. Oksanen K, Kekomaki R, Ruutu T, Koskimies S, Myllyla G: Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components - A randomized trial. Transfusion 31: 588-594, 1991
25. van Marwijk Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman JW: Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: A prospective, randomized trial. Blood 77: 201-205, 1991
26. Williamson LM, Wimperis JZ, Williamson P, Copplestone JA, Gooi HC, Morgenstern GR, Norfolk DR: Bedside filtration of blood products in the prevention of HLA alloimmunization - A prospective randomized study. Alloimmunisation Study Group. Blood 83: 3028-3035, 1994
27. TRAP Investigators: Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 337: 1861-1869, 1997
28. van de Watering L, Hermans J, Witvliet M, Versteegh M, Brand A: HLA and RBC immunization after filtered and buffy coat-depleted blood transfusion in cardiac surgery: A randomized controlled trial. Transfusion 43: 765-771, 2003
29. Pfaff WW, Howard RJ, Scornik JC, Day C, Renderer J, Scott J, Fennel RS, Peterson JC, Salomon DR, Patton PR: Incidental and purposeful random donor blood transfusion. Sensitization and transplantation. Transplantation 47: 130-133, 1989
30. Salvatierra O Jr, Iwaki Y, Vincenti F, Amend W, Potter D, Opelz G, Terasaki P, Duca R, Hopper S, Feduska N: Incidence, characteristics, and outcome of recipients sensitized after donor-specific blood transfusions. Transplantation 32: 528-531, 1981
31. d'Apice AJ, Tait BD: An elective transfusion policy: Sensitization rates, patient transplantability, and transplant outcome. Transplantation 33: 191-195, 1982
32. Bryan CF, Baier KA, Nelson PW, Luger AM, Martinez J, Pierce GE, Ross G, Shiel CF, Warady BA, Aeder MI, Helling TS, Muruve N: Long-term graft survival is improved in cadaveric renal retransplantation by flow cytometric crossmatching. Transplantation 66: 1827-1832, 1998
33. LeFor WM, Ackerman JRW, Alveranga DY, Bowers VD, Heinrichs DF, Kahana L, Shires DL, Weinstein SS, Wright CE: Flow cytometry crossmatching and primary cadaver kidney graft outcome: Relevance of T and B cell targets, historic sera and autologous controls. Clin Transplant 10: 601-606, 1996
34. Mahoney RJ, Ault KA, Given SR, Adams RJ, Breggia AC, Paris PA, Palomaki GE, Hitchcox SA, White BW, Himmelfarb J, Leeber DA: The flow cytometric crossmatch and early renal transplant loss. Transplantation 49: 527-535, 1990
35. Burlingham WJ, Stratta R, Mason B, Lorentzen D, Feyzi J, Sollinger HW, Belzer FO: Risk factors for sensitization by blood transfusions. Comparison of the UW/Madison and UC/San Francisco donor-specific transfusion experience. Transplantation 47: 140-144, 1989
36. Colombe BW, Juster RP, Salvatierra O Jr, Garovoy MR: Prediction of donor-specific transfusion sensitization. I. A linear logistic model. Transplantation 45: 101-105, 1988
37. Dzik WH: Leukoreduction of blood components. Curr Opin Hematol 9: 521-526, 2002
38. Karger R, Kretschmer V: Inline-filtration. Transfus Apheresis Sci 27: 137-152, 2002
39. Fergusson D, Hebert P, Shapiro S: The before/after study design in transfusion medicine: Methodologic considerations. Transfus Med Rev 16: 296-303, 2002
40. Bodensteiner DC: Leukocyte depletion filters: A comparison of efficiency. Am J Hematol 35: 184-186, 1990
41. Riggert J, Simson G, Dittmann J, Kohler M: Prestorage leukocyte depletion with in-line filtration of whole blood in comparison with blood component leukocyte depletion. Vox Sang 69: 201-205, 1995
42. Rapaille A, Moore G, Siquet J, Flament J, Sondag-Thull D: Prestorage leukocyte reduction with in-line filtration of whole blood: Evaluation of red cells and plasma storage. Vox Sang 73: 28-35, 1997
43. Semple JW, Speck ER, Cosgrave D, Lazarus AH, Blanchette VS, Freedman J: Extreme leukoreduction of major histocompatibility complex class II positive B cells enhances allogeneic platelet immunity. Blood 93: 713-720, 1999
44. Dzik S, Szuflad P, Eaves S: HLA antigens on leukocyte fragments and plasma proteins: Prestorage leukoreduction by filtration. Vox Sang 66: 104-111, 1994
45. Everett ET, Kao KJ, Scornik JC: Class I HLA molecules on human erythrocytes. Quantitation and transfusion effects. Transplantation 44: 123-129, 1987
46. Botto M, So AK, Giles CM, Mason PD, Walport MJ: HLA class I expression on erythrocytes and platelets from patients with systemic lupus erythematosus, rheumatoid arthritis and from normal subjects. Br J Haematol 75: 106-111, 1990
47. Salvatierra O Jr, Melzer J, Potter D, Garovoy M, Vincenti F, Amend WJ, Husing R, Hopper S, Feduska NJ: A seven-yearexperience with donor-specific blood transfusions. Results and considerations for maximum efficacy. Transplantation 40: 654-659, 1985
48. Colombe BW, Lou CD, Salvatierra O Jr, Garovoy MR: Two patterns of sensitization demonstrated by recipients of donor-specific transfusion. Limitations to control by Imuran. Transplantation 44: 509-515, 1987
49. Raftery MJ, Lang CJ, O'Shea JM, Varghese Z, Sweny P, Fernando ON, Moorhead JF: Controlled trial of azathioprine and cyclosporin to prevent anti-HLA antibodies due to third-party transfusion. Nephrol Dial Transplant 3: 671-676, 1988
50. Scornik JC, Salomon DR, Howard RJ, Pfaff WW: Prevention of transfusion-induced broad sensitization in renal transplant candidates. Transplantation 47: 617-620, 1989
51. Lagaaij EL, Hennemann IP, Ruigrok M, de Haan MW, Persijn GG, Termijtelen A, Hendricks GF, Weimar W, Claas FH, van Rood JJ: Effect of one-HLA-DR-antigen-matched and completely HLA-DR-mismatched blood transfusions on survival of heart and kidney allografts. N Engl J Med 321: 701-705, 1989
52. Winslow RM: Blood substitutes. Curr Opin Hematol 9: 146-151, 2002
53. Goodnough LT, Shander A, Brecher ME: Transfusion medicine: Looking to the future. Lancet 361: 161-169, 2003